Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

First results of the What’s the STORY (Serum Testing Of Representative Youngsters) trial indicate higher resilience of children to COVID-19 compared to other respiratory illnesses.

Boy and girl playing piggyback rides. © Image by Pexels

What’s the STORY – a study run by the Oxford Vaccine Group in collaboration with Public Health England and funded by the National Institute for Health Research – investigates the prevalence of COVID-19 in children. Assessing the rates of coronavirus infection and immunity in children and teenagers will help to identify their role in spreading the disease, thus providing essential data for guiding governmental response to the pandemic.

The nationwide trial, commenced in February 2020, is led by Professor Matthew Snape from the Oxford Vaccine Group. As part of the study, OVG researchers assess the participants’ immunity by checking for coronavirus antibodies – the presence of which indicates that a child has already had COVID-19, even though they might not necessarily have shown symptoms.

Initial results of the trial show that between 3 and 4 percent of children in the study tested positive for antibodies – however, of those who tested positive, fewer than 10 percent showed any symptoms of COVID-19. The proportion of participants with detected antibodies was much higher in London than in other study sites.

These results suggest that although very few children and teenagers are experiencing COVID-19 symptoms, their infection rates are not that different from those seen in adults. Together with other studies this indicates COVID-19 does not spread readily via children, making it very different to other respiratory diseases, such as influenza. The finding “provides some reassurance when it comes to opening schools”, stated Professor Snape in an interview for BBC Newsnight.

More information about the study can be found on the What’s the STORY trial website, and the NIHR site.

Listen to Deb Cohen's interview with Professor Matthew Snape's on BBC Newsnight:

Similar stories

Oxford University extends COVID-19 vaccine study to children

COVID-19 Research

The University of Oxford, together with three partner sites in London, Southampton and Bristol, is to launch the first study to assess the safety and immune responses in children and young adults of the ChAdOx1 nCoV-19 coronavirus vaccine.

World Health Organization experts provide guidance on use of the Oxford vaccine

COVID-19 Research

WHO SAGE says Oxford's coronavirus vaccine is safe and likely to be efficacious in older adults, and recommends its use in this age group.

Oxford leads first trial investigating dosing with alternating vaccines

COVID-19 Research

The Oxford Vaccine Group is to lead the first trial to explore alternating different COVID-19 vaccines, to explore the potential for flexibility in delivery and look for clues as to how to increase the breadth of protection against new virus strains.

Oxford University vaccine developer joins day of vaccinations at the Kassam Stadium

COVID-19

Today, Andrew Pollard, Professor of Pediatric Infection and Immunity at the University of Oxford, and chief investigator of the trials of the ChAdOx1 nCoV-19 coronavirus vaccine, volunteered his time to help deliver live-saving Covid vaccinations at the newly opened NHS Vaccine Centre at the Kassam Stadium, Oxford.

Oxford vaccine researchers talk research and home-schooling on ITV's This Morning

COVID-19 Public Engagement

Professor Katie Ewer (The Jenner Institute) and Dr Maheshi Ramasamy (Oxford Vaccine Group) appeared on ITV's This Morning on Wednesday 6 January to talk about their work developing the ChAdOx1 nCoV-19 coronavirus vaccine, all while juggling the demands of young families and home-schooling.